EA
EFG Asset Management (North America) Corp.
13F filer · CIK 0001911412Last filed Nov 3, 2025
Inactive · not filing 13F
13F portfolio value$773MU.S. long equity reported on 13F
Positions16721 new · 13 closed
Net flow last quarter-$591KBuys minus sells
Top 10 positions weight20.0%Concentration
Holdings
13F · last 4 quarters freeScroll for earlier quarters
| Company | Value | % of portfolio | % of company | POSITION CHANGE qoq % | First reported |
|---|---|---|---|---|---|
| Q3 2025Reported Nov 3, 2025167 positions | |||||
| $25.9M | 3.35% | 0.00% | -4.8% | Q4 2021 | |
| $19.6M | 2.54% | 0.00% | +3.6% | Q4 2021 | |
| $19.4M | 2.51% | 0.00% | -19.0% | Q4 2021 | |
| $18.1M | 2.34% | 0.00% | +25.1% | Q4 2021 | |
| $17.8M | 2.30% | Not reported | +7.0% | Q4 2021 | |
| $13.8M | 1.78% | 0.00% | +20.8% | Q1 2022 | |
| $10.6M | 1.37% | 0.00% | +2.0% | Q4 2021 | |
| $10.3M | 1.34% | 0.02% | -22.1% | Q1 2024 | |
| $9.82M | 1.27% | 0.00% | -24.6% | Q1 2025 | |
| $9.38M | 1.21% | 0.01% | +22.2% | Q1 2025 | |
| $9.03M | 1.17% | 0.00% | -3.0% | Q2 2023 | |
| $8.25M | 1.07% | 0.01% | -9.5% | Q4 2023 | |
| $8.2M | 1.06% | 0.00% | +6.7% | Q4 2021 | |
| $7.83M | 1.01% | 0.13% | +15.5% | Q4 2021 | |
| $7.56M | 0.98% | 0.28% | +6.1% | Q4 2021 | |
| $7.53M | 0.97% | 0.01% | +27.8% | Q4 2021 | |
| $7.44M | 0.96% | 0.01% | -22.8% | Q1 2022 | |
| $7.19M | 0.93% | 0.02% | -3.6% | Q4 2021 | |
| $7.11M | 0.92% | 0.00% | +3.6% | Q4 2021 | |
| $6.98M | 0.90% | 0.01% | +35.4% | Q1 2023 | |
| $6.89M | 0.89% | 0.04% | -27.7% | Q2 2024 | |
| $6.81M | 0.88% | 0.01% | +10.9% | Q3 2022 | |
| $6.74M | 0.87% | 0.06% | -22.9% | Q3 2023 | |
| $6.55M | 0.85% | 0.00% | +9.0% | Q4 2021 | |
| $6.51M | 0.84% | 0.01% | -13.4% | Q4 2021 | |
| ABRNAMAvidity Biosciences, Inc. | $6.5M | 0.84% | 0.10% | -12.0% | Q2 2024 |
| $6.48M | 0.84% | 0.01% | -8.8% | Q4 2021 | |
| $6.24M | 0.81% | 0.01% | +28.1% | Q1 2024 | |
| $6.2M | 0.80% | 0.00% | +3.6% | Q4 2021 | |
| $6.2M | 0.80% | 0.00% | +3.6% | Q4 2021 | |
| $6M | 0.78% | 0.00% | -30.7% | Q1 2024 | |
| $5.92M | 0.77% | 0.24% | +3.4% | Q4 2021 | |
| $5.92M | 0.77% | 0.07% | -17.8% | Q1 2024 | |
| $5.82M | 0.75% | 0.07% | -23.9% | Q4 2021 | |
| $5.79M | 0.75% | 0.04% | -12.7% | Q4 2024 | |
| $5.74M | 0.74% | 0.06% | +13.6% | Q4 2024 | |
| $5.72M | 0.74% | 0.07% | +1.1% | Q4 2021 | |
| $5.68M | 0.73% | 0.01% | +22.3% | Q2 2025 | |
| $5.67M | 0.73% | 0.00% | -9.2% | Q4 2021 | |
| $5.55M | 0.72% | 0.00% | +21.9% | Q4 2021 | |
| $5.5M | 0.71% | 0.07% | -9.3% | Q2 2025 | |
| $5.49M | 0.71% | 0.13% | +1.1% | Q1 2025 | |
| $5.41M | 0.70% | 0.00% | +17.9% | Q2 2022 | |
| $5.37M | 0.69% | 0.12% | +29.7% | Q4 2021 | |
| $5.32M | 0.69% | 0.10% | +1.2% | Q2 2024 | |
| $5.27M | 0.68% | 0.08% | +14.9% | Q4 2021 | |
| $5.19M | 0.67% | Not reported | -9.5% | Q2 2024 | |
| $5.19M | 0.67% | 0.00% | +3.6% | Q2 2023 | |
| $5.18M | 0.67% | 0.05% | +38.2% | Q2 2025 | |
| $5.16M | 0.67% | 0.00% | -22.8% | Q4 2021 | |
| Q2 2025Reported Aug 6, 2025159 positions | |||||
| $23M | 3.26% | 0.00% | -1.1% | Q4 2021 | |
| $18.9M | 2.67% | 0.00% | +2.5% | Q4 2021 | |
| $17.4M | 2.46% | 0.00% | +2.5% | Q4 2021 | |
| $16.7M | 2.37% | Not reported | -3.6% | Q4 2021 | |
| $12.1M | 1.71% | 0.00% | -11.7% | Q4 2021 | |
| $11.6M | 1.64% | 0.00% | +27.0% | Q1 2022 | |
| $11.6M | 1.64% | 0.00% | +1.3% | Q4 2021 | |
| $11.3M | 1.60% | 0.02% | +23.1% | Q1 2024 | |
| $10.5M | 1.48% | 0.02% | +17.8% | Q4 2023 | |
| $7.31M | 1.03% | 0.00% | -8.9% | Q4 2021 | |
| $7.26M | 1.03% | 0.02% | -12.5% | Q4 2021 | |
| $7.07M | 1.00% | 0.01% | +124.8% | Q1 2025 | |
| $6.89M | 0.97% | 0.02% | -14.3% | Q1 2022 | |
| $6.82M | 0.96% | 0.00% | +2.5% | Q4 2021 | |
| $6.68M | 0.94% | 0.00% | +2.5% | Q4 2021 | |
| $6.64M | 0.94% | 0.01% | +17.7% | Q3 2022 | |
| $6.54M | 0.92% | 0.01% | +32.7% | Q2 2023 | |
| $6.46M | 0.91% | 0.00% | -65.5% | Q1 2024 | |
| $6.4M | 0.90% | 0.00% | +5.5% | Q4 2021 | |
| $6.39M | 0.90% | 0.03% | -32.6% | Q4 2021 | |
| $6.35M | 0.90% | 0.01% | +156.3% | Q1 2025 | |
| $6.27M | 0.89% | 0.00% | +27.9% | Q4 2021 | |
| $6.03M | 0.85% | 0.09% | -2.1% | Q1 2024 | |
| $5.97M | 0.84% | 0.00% | +38.0% | Q4 2021 | |
| $5.97M | 0.84% | 0.07% | -0.1% | Q4 2024 | |
| $5.96M | 0.84% | 0.01% | -8.5% | Q4 2021 | |
| $5.94M | 0.84% | 0.08% | -28.2% | Q3 2023 | |
| $5.89M | 0.83% | 0.27% | +35.4% | Q2 2023 | |
| BMBPMCBlueprint Medicines Corporation | $5.88M | 0.83% | 0.07% | -37.6% | Q4 2021 |
| $5.86M | 0.83% | 0.00% | +91.3% | Q4 2021 | |
| $5.75M | 0.81% | 0.02% | -4.1% | Q4 2021 | |
| $5.73M | 0.81% | 0.10% | +4.5% | Q4 2021 | |
| $5.71M | 0.81% | Not reported | -0.9% | Q4 2021 | |
| $5.6M | 0.79% | 0.26% | +3.9% | Q4 2021 | |
| $5.59M | 0.79% | 0.00% | +2.5% | Q4 2021 | |
| $5.57M | 0.79% | 0.02% | -6.0% | Q4 2021 | |
| $5.55M | 0.78% | 0.14% | +10.8% | Q2 2023 | |
| $5.52M | 0.78% | 0.14% | +12.9% | Q2 2024 | |
| $5.43M | 0.77% | 0.09% | +1.3% | Q4 2021 | |
| $5.35M | 0.76% | 0.05% | -0.9% | Q4 2024 | |
| $5.29M | 0.75% | 0.01% | -6.7% | Q1 2023 | |
| $5.29M | 0.75% | Not reported | -13.2% | Q2 2023 | |
| $5.22M | 0.74% | 0.07% | -10.1% | Q4 2021 | |
| $5.16M | 0.73% | 0.00% | +20.6% | Q4 2021 | |
| $5.01M | 0.71% | Not reported | +11.5% | Q2 2024 | |
| $4.99M | 0.70% | 0.00% | +22.7% | Q2 2022 | |
| $4.94M | 0.70% | 0.14% | +10.5% | Q1 2023 | |
| $4.85M | 0.68% | 0.14% | -15.0% | Q3 2024 | |
| $4.84M | 0.68% | 0.06% | -31.2% | Q2 2024 | |
| $4.83M | 0.68% | 0.01% | +36.9% | Q1 2024 | |
| Q1 2025Reported May 15, 2025175 positions | |||||
| $16.1M | 2.67% | 0.00% | -16.3% | Q4 2021 | |
| $16M | 2.66% | 0.00% | -10.2% | Q4 2021 | |
| $14.9M | 2.47% | 0.00% | -3.5% | Q4 2021 | |
| $13.6M | 2.25% | Not reported | -3.7% | Q4 2021 | |
| $12.6M | 2.10% | 0.00% | -36.0% | Q4 2021 | |
| $11.6M | 1.92% | 0.01% | -20.5% | Q1 2024 | |
| $9.71M | 1.61% | 0.00% | +249.6% | Q1 2022 | |
| $8.32M | 1.38% | 0.00% | -7.0% | Q4 2021 | |
| $8M | 1.33% | 0.00% | -5.3% | Q4 2021 | |
| $7.31M | 1.21% | 0.00% | -20.9% | Q4 2021 | |
| $7.18M | 1.19% | 0.05% | -12.5% | Q4 2021 | |
| $6.68M | 1.11% | 0.02% | -16.6% | Q4 2021 | |
| $6.67M | 1.11% | 0.02% | -7.3% | Q1 2022 | |
| $6.57M | 1.09% | 0.08% | -19.6% | Q4 2021 | |
| $6.57M | 1.09% | 0.00% | -19.7% | Q4 2021 | |
| BMBPMCBlueprint Medicines Corporation | $6.5M | 1.08% | 0.11% | -1.2% | Q4 2021 |
| $6.37M | 1.06% | 0.02% | -26.0% | Q4 2021 | |
| $5.92M | 0.98% | 0.26% | -3.2% | Q4 2021 | |
| $5.8M | 0.96% | 0.00% | -13.6% | Q4 2021 | |
| $5.67M | 0.94% | 0.01% | +25.7% | Q4 2023 | |
| $5.34M | 0.89% | 0.00% | +8.4% | Q4 2021 | |
| $5.26M | 0.87% | 0.08% | -0.4% | Q4 2021 | |
| $5.22M | 0.87% | 0.09% | -12.4% | Q4 2021 | |
| $5.17M | 0.86% | 0.02% | +48.5% | Q1 2024 | |
| $5.1M | 0.85% | 0.02% | -9.1% | Q4 2021 | |
| $5.05M | 0.84% | 0.00% | +6.0% | Q4 2021 | |
| $5.02M | 0.83% | 0.03% | -19.4% | Q4 2021 | |
| $4.95M | 0.82% | 0.05% | +24.6% | Q4 2024 | |
| $4.91M | 0.82% | 0.03% | -26.8% | Q3 2024 | |
| $4.85M | 0.81% | 0.01% | -20.8% | Q1 2023 | |
| $4.78M | 0.79% | 0.01% | -17.1% | Q3 2022 | |
| ABRNAMAvidity Biosciences, Inc. | $4.59M | 0.76% | 0.13% | +30.1% | Q2 2024 |
| $4.55M | 0.76% | 0.20% | -3.7% | Q2 2023 | |
| $4.53M | 0.75% | 0.06% | -0.9% | Q3 2024 | |
| $4.49M | 0.75% | 0.10% | -20.0% | Q2 2024 | |
| $4.45M | 0.74% | 0.13% | -11.8% | Q1 2023 | |
| $4.43M | 0.74% | 0.00% | -24.3% | Q2 2022 | |
| $4.32M | 0.72% | 0.31% | -11.7% | Q4 2021 | |
| $4.21M | 0.70% | Not reported | -0.6% | Q2 2024 | |
| $4.1M | 0.68% | 0.10% | -0.3% | Q3 2023 | |
| $4.09M | 0.68% | 0.00% | -13.6% | Q4 2021 | |
| $4.07M | 0.68% | 0.00% | -13.7% | Q4 2021 | |
| $4.06M | 0.67% | 0.12% | -3.2% | Q3 2023 | |
| $4.04M | 0.67% | 0.12% | -21.3% | Q2 2023 | |
| $4M | 0.66% | 0.00% | -9.3% | Q4 2021 | |
| $4M | 0.66% | 0.07% | +13.3% | Q4 2024 | |
| $3.86M | 0.64% | Not reported | +38.0% | Q4 2021 | |
| $3.84M | 0.64% | 0.09% | -0.3% | Q1 2024 | |
| $3.73M | 0.62% | 0.00% | -0.6% | Q2 2023 | |
| $3.71M | 0.62% | 0.08% | +15.6% | Q4 2021 | |
| Q4 2024Reported Feb 11, 2025173 positions | |||||
| $23.7M | 3.23% | 0.00% | +12.1% | Q4 2021 | |
| $22.2M | 3.04% | 0.00% | +13.2% | Q4 2021 | |
| $20.5M | 2.81% | 0.00% | +17.1% | Q4 2021 | |
| $18.9M | 2.58% | 0.00% | +1.6% | Q4 2021 | |
| $14.3M | 1.95% | Not reported | +5.4% | Q4 2021 | |
| $13.1M | 1.78% | 0.01% | +59.5% | Q1 2024 | |
| $12.4M | 1.69% | 0.00% | +15.5% | Q4 2021 | |
| $9.74M | 1.33% | 0.01% | -9.2% | Q4 2021 | |
| $9.1M | 1.24% | 0.11% | +106.7% | Q4 2021 | |
| $8.94M | 1.22% | 0.02% | +3.1% | Q4 2021 | |
| $8.16M | 1.11% | 0.27% | +1.0% | Q4 2021 | |
| $8.08M | 1.10% | 0.00% | +22.3% | Q4 2021 | |
| $7.43M | 1.01% | 0.06% | +111.6% | Q4 2021 | |
| $7.39M | 1.01% | 0.00% | +22.7% | Q4 2021 | |
| $7.27M | 0.99% | 0.02% | -4.7% | Q4 2021 | |
| $6.97M | 0.95% | 0.03% | -17.5% | Q4 2021 | |
| $6.96M | 0.95% | 0.01% | +57.1% | Q3 2022 | |
| $6.65M | 0.91% | 0.01% | +76.1% | Q1 2023 | |
| $6.51M | 0.89% | 0.00% | +9.1% | Q4 2021 | |
| BMBPMCBlueprint Medicines Corporation | $6.48M | 0.88% | 0.12% | +120.6% | Q4 2021 |
| $6.35M | 0.87% | 0.00% | +9.3% | Q4 2021 | |
| $6.28M | 0.86% | 0.02% | +29.3% | Q1 2022 | |
| $6.24M | 0.85% | 0.12% | +58.6% | Q3 2023 | |
| ITITCIIntra-Cellular Therapies, Inc. | $6.2M | 0.85% | 0.07% | +99.8% | Q4 2021 |
| $6.13M | 0.84% | 0.10% | +18.3% | Q4 2021 | |
| $6.03M | 0.82% | 0.35% | +48.1% | Q4 2021 | |
| $5.96M | 0.81% | 0.16% | +86.7% | Q2 2023 | |
| $5.86M | 0.80% | 0.15% | +27.5% | Q1 2023 | |
| $5.84M | 0.80% | 0.01% | +74.6% | Q2 2024 | |
| $5.82M | 0.79% | 0.21% | +83.6% | Q2 2023 | |
| $5.58M | 0.76% | 0.04% | +32.3% | Q3 2024 | |
| $5.53M | 0.76% | 0.02% | -1.9% | Q4 2021 | |
| $5.48M | 0.75% | 0.01% | +41.9% | Q1 2024 | |
| $5.44M | 0.74% | 0.00% | +6.1% | Q4 2021 | |
| $5.36M | 0.73% | Not reported | +172.4% | Q2 2024 | |
| $5.35M | 0.73% | 0.00% | +9.4% | Q2 2023 | |
| $5.23M | 0.71% | 0.00% | -3.6% | Q4 2021 | |
| $5.1M | 0.70% | 0.01% | +9.0% | Q4 2023 | |
| $5.05M | 0.69% | 0.00% | +57.3% | Q4 2021 | |
| $5.04M | 0.69% | 0.08% | +58.6% | Q4 2021 | |
| $4.99M | 0.68% | 0.13% | +59.1% | Q2 2024 | |
| $4.86M | 0.66% | 0.00% | +49.0% | Q2 2022 | |
| $4.74M | 0.65% | 0.10% | +169.6% | Q3 2023 | |
| $4.72M | 0.64% | 0.01% | +8.9% | Q4 2021 | |
| $4.69M | 0.64% | 0.01% | +29.9% | Q4 2021 | |
| $4.66M | 0.64% | Not reported | +83.8% | Q4 2021 | |
| $4.52M | 0.62% | 0.01% | +9.3% | Q4 2021 | |
| $4.4M | 0.60% | 0.09% | +58.4% | Q1 2024 | |
| $4.38M | 0.60% | 0.05% | +103.8% | Q2 2024 | |
| $4.29M | 0.59% | Not reported | +40.0% | Q4 2021 | |
Premium opens every quarter this fund has filed